SWISSto12 raised $70M, and it is that rare thing: a profitable space startup
THE SO WHAT
A profitable space-hardware company raising $70M on top of €84.8M from ESA shows sovereign customers will bankroll dual-use infrastructure that can stand on its own P&L. If you’re building in space or other capex-heavy domains, anchoring around government-backed programs is still the cleanest path to durable margins.
READ THE SOURCE
MORE FROM THE WIRE
Deep & Emerging TechMicron has turned into ‘the most important stock in the market.’ So is it time to worry?
When Micron becomes 'the most important stock,' you're no longer just trading memory—you’re trading AI demand expectations and capex cycles. Operators relying on GPU and HBM availability should treat DRAM vendors as strategic partners and leading indicators, not commodity suppliers.
Deep & Emerging TechAI and a brain implant restored a paralysed man’s movement and touch
A double neural bypass restoring movement and touch—and partially rewiring the nervous system—moves BCIs from lab demo toward durable therapy. Healthcare operators should start mapping where closed-loop AI + implants could change long-term care models, reimbursement, and rehab infrastructure.
Deep & Emerging Tech47 requests, zero answers — How Proton VPN keeps saying no to data demands
Forty-seven data requests and zero disclosures is a live proof that audited no-logs architectures can withstand legal pressure. If your product markets on privacy, you need this level of technical and policy alignment—not just a line in the FAQ.
Deep & Emerging TechKalshi Is Set to Start Taking Bets on Drug Trials
Letting retail traders bet on drug trial outcomes expands the surface area for information leakage and market manipulation in biotech. If you operate in or around clinical data, tighten access controls and comms discipline—your timelines just became a speculative asset.